Dr Hidenori Toyoda and colleagues from Japan evaluated the prognostic value of the pretreatment elevation of tumor markers for hepatocellular carcinoma in patients who underwent curative treatment.
The research team studied 801 patients who had been diagnosed as initial hepatocellular carcinoma.
The patients had a maximum tumor size of 3cm, and maximum number of 3 tumors, had remnant liver function, and were Child-Pugh class A or B.
The patients were also treated by hepatectomy or locoregional thermal ablation.
|Des-gamma carboxy prothrombin elevation had the strongest effect on patient survival|
|Journal of Hepatology|
Alpha-fetoprotein, lens culinaris agglutinin A-reactive fraction of alpha-fetoprotein, and des-gamma carboxy prothrombin were measured at diagnosis.
The research team analyzed the effects of elevated tumor markers on patient survival in these 2 distinct groups with different types of treatment.
The team found that in 345 patients who underwent hepatectomy, no tumor marker significantly affected decreased survival rate.
In the 456 patients who underwent locoregional thermal ablation, with elevation of lens culinaris agglutinin A-reactive fraction of alpha-fetoprotein, and des-gamma carboxy prothrombin significantly affected decreased survival rate.
Des-gamma carboxy prothrombin elevation had the strongest effect on patient survival.
Dr Toyoda's team commented, "Prognostic value of pretreatment tumor marker elevation was different in patients who underwent the curative treatment according to the type of treatment."
"Pretreatment elevation of lens culinaris agglutinin A-reactive fraction of alpha-fetoprotein and des-gamma carboxy prothrombin had prognostic values only in patients treated with locoregional thermal ablation."